Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Bausch + Lomb Corporation before investing.

In this article, we go over a few key elements for understanding Bausch + Lomb Corporation’s stock price such as:

• Bausch + Lomb Corporation’s current stock price and volume
• Why Bausch + Lomb Corporation’s stock price changed recently
• Upgrades and downgrades for BLCO from analysts
• BLCO’s stock price momentum as measured by its relative strength

About Bausch + Lomb Corporation (BLCO)

Before we jump into Bausch + Lomb Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Want to learn more about Bausch + Lomb Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Bausch + Lomb Corporation.

Bausch + Lomb Corporation’s Stock Price as of Market Close

As of October 30, 2026, 4:00 PM, CST, Bausch + Lomb Corporation’s stock price was $20.000.

Bausch + Lomb Corporation is down 1.96% from its previous closing price of $20.400.

During the last market session, Bausch + Lomb Corporation’s stock traded between $19.830 and $20.850. Currently, there are approximately 357.10 million shares outstanding for Bausch + Lomb Corporation.

Bausch + Lomb Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Bausch + Lomb Corporation Stock Price History

Bausch + Lomb Corporation’s (BLCO) price is currently up 17.65% so far this month.

During the month of October, Bausch + Lomb Corporation’s stock price has reached a high of $21.360 and a low of $15.470.

Over the last year, Bausch + Lomb Corporation has hit prices as high as $21.360 and as low as $14.440. Year to date, Bausch + Lomb Corporation’s stock is up 17.1%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Bausch + Lomb Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of October 30, 2026, there were 2 analysts who downgraded Bausch + Lomb Corporation’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Bausch + Lomb Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Bausch + Lomb Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Bausch + Lomb Corporation’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Bausch + Lomb Corporation (BLCO) by visiting AAII Stock Evaluator.

Relative Price Strength of Bausch + Lomb Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of October 30, 2026, Bausch + Lomb Corporation has a weighted four-quarter relative price strength of 8.49%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Bausch + Lomb Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Bausch + Lomb Corporation Stock Price: Bottom Line

As of October 30, 2026, Bausch + Lomb Corporation’s stock price is $20.000, which is down 1.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Bausch + Lomb Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.